Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega(Versar (United States)), C. Michael Gibson(Baim Institute for Clinical Research), Shinya Goto(Tokai University), Paul Burton(Newcastle University), Keith A.A. Fox(University of Edinburgh), Jean‐Pierre Bassand(Observatoire des Sciences de l’Univers Terre Homme Environnement Temps Astronomie), Marc Cohen(Newark Beth Israel Medical Center), Freek W.A. Verheugt(Radboud University Nijmegen), Sabina A. Murphy(Brigham and Women's Hospital), Nancy Cook‐Bruns(Bayer (Germany)), Xiang Sun(Johnson & Johnson (United States)), David J. Schneider(Schneider Electric (France)), Christoph Bode(University Medical Center Freiburg), Stephen D. Wiviott(Brigham and Women's Hospital), Eugene Braunwald(Mass General Brigham), Alexei N. Plotnikov(Johnson & Johnson (United States)), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 1,886
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs
|JAMA|2016|7.5k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k